

Carla Felice

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/787952/publications.pdf>

Version: 2024-02-01

64
papers

1,690
citations

331670

21
h-index

289244

40
g-index

64
all docs

64
docs citations

64
times ranked

3067
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of COVID-19 Outbreak on Healthcare Workers in Italy: Results from a National E-Survey. <i>Journal of Community Health</i> , 2020, 45, 675-683.	3.8	139
2	Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 26-38.	3.7	104
3	Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 880-888.	3.7	94
4	Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti-TNF agents: Effects of combined therapy with immunosuppressants. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 301-307.	1.3	86
5	Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: An open-label pilot study. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e623-e629.	1.3	85
6	Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. <i>Autoimmunity Reviews</i> , 2014, 13, 822-830.	5.8	84
7	Management of perianal fistulas in Crohn's disease: An up-to-date review. <i>World Journal of Gastroenterology</i> , 2015, 21, 1394.	3.3	82
8	Anti TNF therapy for ulcerative colitis: current status and prospects for the future. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 223-233.	3.0	78
9	Use of RAAS Inhibitors and Risk of Clinical Deterioration in COVID-19: Results From an Italian Cohort of 133 Hypertensives. <i>American Journal of Hypertension</i> , 2020, 33, 944-948.	2.0	72
10	Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor agents. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 113-119.	1.3	68
11	Infliximab in Steroid-dependent Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1065-1072.	1.9	66
12	Role of HMGB1 as a Suitable Biomarker of Subclinical Intestinal Inflammation and Mucosal Healing in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1448-1457.	1.9	66
13	Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year. <i>Digestive and Liver Disease</i> , 2014, 46, 974-979.	0.9	64
14	Venous thromboembolism in patients with inflammatory bowel disease: Focus on prevention and treatment. <i>World Journal of Gastroenterology</i> , 2014, 20, 3173.	3.3	63
15	Vascular Involvement in Inflammatory Bowel Disease: Pathogenesis and Clinical Aspects. <i>Digestive Diseases</i> , 2008, 26, 149-155.	1.9	60
16	Long-term Combination Therapy with Infliximab Plus Azathioprine Predicts Sustained Steroid-free Clinical Benefit in Steroid-dependent Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1368-1374.	1.9	55
17	Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1079-1088.	1.3	50
18	Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1426-1432.e1.	4.4	39

#	ARTICLE	IF	CITATIONS
19	Use of Infliximab in Particular Clinical Settings: Management Based on Current Evidence. American Journal of Gastroenterology, 2009, 104, 1575-1586.	0.4	37
20	FOXP3 ⁺ T Regulatory Cell Modifications in Inflammatory Bowel Disease Patients Treated with Anti-TNF α Agents. BioMed Research International, 2013, 2013, 1-10.	1.9	31
21	Red flags for appropriate referral to the gastroenterologist and the rheumatologist of patients with inflammatory bowel disease and spondyloarthritis. Clinical and Experimental Immunology, 2019, 196, 123-138.	2.6	27
22	Total Abdominal Colectomy for Refractory Ulcerative Colitis. Surgical Treatment in Evolution. Journal of Gastrointestinal Surgery, 2011, 15, 1909-1916.	1.7	21
23	Ileal Crohn's disease: CEUS determination of activity. Abdominal Imaging, 2012, 37, 359-368.	2.0	21
24	Biological therapies for inflammatory bowel disease: controversies and future options. Expert Review of Clinical Pharmacology, 2009, 2, 391-403.	3.1	18
25	Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases. Expert Review of Clinical Immunology, 2018, 14, 751-759.	3.0	14
26	Risk factors and timing for colectomy in chronically active refractory ulcerative colitis: A systematic review. Digestive and Liver Disease, 2019, 51, 613-620.	0.9	14
27	The miR-200 family is increased in dysplastic lesions in ulcerative colitis patients. PLoS ONE, 2017, 12, e0173664.	2.5	14
28	Therapeutic drug monitoring of anti-TNF α agents in inflammatory bowel diseases. Expert Opinion on Biological Therapy, 2015, 15, 1107-1117.	3.1	13
29	Multidisciplinary management of patients with coexisting inflammatory bowel disease and spondyloarthritis: A Delphi consensus among Italian experts. Digestive and Liver Disease, 2017, 49, 1298-1305.	0.9	13
30	Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients. Journal of Gastrointestinal and Liver Diseases, 2013, 22, 21-5.	0.9	13
31	AID in aging and autoimmune diseases. Autoimmunity, 2013, 46, 168-175.	2.6	11
32	GSK-3 Inhibition Modulates Metalloproteases in a Model of Lung Inflammation and Fibrosis. Frontiers in Molecular Biosciences, 2021, 8, 633054.	3.5	10
33	Comment on: Emergence of severe spondyloarthropathy-related enthesal pathology following successful vedolizumab therapy for inflammatory bowel disease. Rheumatology, 2019, 58, 1113-1115.	1.9	9
34	Intestinal Inflammation is Linked to Hypoacetylation of Histone 3 Lysine 27 and can be Reversed by Valproic Acid Treatment in Inflammatory Bowel Disease Patients. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 889-891.e6.	4.5	8
35	Etolizumab in moderate-to-severe ulcerative colitis. Lancet, The, 2014, 384, 285-286.	13.7	7
36	Coronavirus disease 2019 in Italy: The Veneto model. Infection Control and Hospital Epidemiology, 2021, 42, 236-237.	1.8	7

#	ARTICLE	IF	CITATIONS
37	Fibrolamellar hepatocellular carcinoma with biliary tumor thrombus: an unreported association. <i>Japanese Journal of Radiology</i> , 2013, 31, 706-712.	2.4	6
38	What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2016, 7, 387.	1.1	6
39	Changes in hospital admissions and complications of acute appendicitis during the COVID-19 pandemic: A systematic review and meta-analysis. <i>Health Sciences Review</i> , 2022, 3, 100021.	1.5	5
40	A Case of Hereditary Hemorrhagic Telangiectasia Associated With Crohn's Disease Successfully Treated With Infliximab. <i>American Journal of Gastroenterology</i> , 2010, 105, 1904.	0.4	4
41	Infliximab dose optimization in IBD—proactive or reactive?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 706-708.	17.8	4
42	The Emerging Role of Nutraceuticals in Cardiovascular Calcification: Evidence from Preclinical and Clinical Studies. <i>Nutrients</i> , 2021, 13, 2603.	4.1	4
43	Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis. <i>Drug, Healthcare and Patient Safety</i> , 2016, 8, 1.	2.5	3
44	Therapeutic Role of Appendectomy in Ulcerative Colitis: A Tangible Perspective?. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 142-143.	1.3	3
45	Comparison between Dexamethasone and Methylprednisolone Therapy in Patients with COVID-19 Pneumonia Admitted to Non-Intensive Medical Units. <i>Journal of Clinical Medicine</i> , 2021, 10, 5812.	2.4	3
46	Intima-Media Thickness in Inflammatory Bowel Disease Patients: A Still Open Question. <i>American Journal of Gastroenterology</i> , 2008, 103, 490-490.	0.4	2
47	Surgical Management of Hemorrhoidal Disease in Inflammatory Bowel Disease: A Systematic Review with Proportional Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 709.	2.4	2
48	Anal Fistula Human Amniotic Membrane Endosealing (F-HAME): A Proof of Concept Study. <i>Frontiers in Surgery</i> , 2022, 9, 869923.	1.4	2
49	342 Retreatment With Infliximab in Inflammatory Bowel Disease: Tolerability and Effectiveness of Different Re-Induction Regimens. <i>Gastroenterology</i> , 2014, 146, S-78-S-79.	1.3	1
50	Acute cytomegalovirus infection as a possible trigger for pulmonary thromboembolism in a patient with steroid-refractory ulcerative colitis. <i>Digestive and Liver Disease</i> , 2014, 46, 290-291.	0.9	1
51	Chest radiography findings of COVID-19 pneumonia: a specific pattern for a confident differential diagnosis. <i>Acta Radiologica</i> , 2022, 63, 1619-1626.	1.1	1
52	W1049 Quantification of Microvascular Activation in Ileal Crohn's Disease By Software Elaboration Data Applied to CEUS: Correlation with Biological Activity Indexes. <i>Gastroenterology</i> , 2009, 136, A-643.	1.3	0
53	In Vivo and In Vitro Immune Response to Pandemic Influenza 2009 H1N1 Vaccine in Inflammatory Bowel Disease Patients on Anti TNF-Alpha Treatment. <i>Gastroenterology</i> , 2011, 140, S-274.	1.3	0
54	Infliximab in Steroid-Dependent Ulcerative Colitis. <i>Gastroenterology</i> , 2011, 140, S-592.	1.3	0

#	ARTICLE	IF	CITATIONS
55	Response to Influenza Vaccine a/H1N1 2009 in Patients With Inflammatory Bowel Disease on Anti TNF-Alpha Therapy. <i>Gastroenterology</i> , 2011, 140, S-274.	1.3	0
56	Total Abdominal Colectomy for Refractory Ulcerative Colitis. Evolution in Surgical Treatment. <i>Gastroenterology</i> , 2011, 140, S-1029.	1.3	0
57	Infliximab: A Review of Its Use in the Treatment of Inflammatory Bowel Disease. <i>Clinical Medicine Insights Therapeutics</i> , 2011, 3, CMT.S1978.	0.4	0
58	Reply to Dr. Kotze's and Dr. Yamamoto's letter. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e699.	1.3	0
59	Inducing remission of ulcerative colitis: are clinicians better equipped than ever?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013, 7, 95-97.	3.0	0
60	19 Infliximab Discontinuation Is Associated With a Higher Risk for Relapse in Patients With Ulcerative Colitis in Remission: A Multinational Collaborative Retrospective Study. <i>Gastroenterology</i> , 2016, 150, S6.	1.3	0
61	Tu1910 Ultrasound and Histologically Proven Paradoxical Arthritis in IBD Patients Treated With Anti-TNF±. <i>Gastroenterology</i> , 2016, 150, S975.	1.3	0
62	Sa1978 Infliximab Trough Levels After Dose Optimization for Loss of Response Predict Outcome at One Year. <i>Gastroenterology</i> , 2016, 150, S422.	1.3	0
63	TREM1 predicts response to anti-tumor necrosis factor in inflammatory bowel diseases: Towards precision medicine. <i>EBioMedicine</i> , 2019, 41, 40-41.	6.1	0
64	The role of healthcare providers in accompanying biosimilars in inflammatory bowel diseases. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 967-969.	3.1	0